Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from HC Wainwright

Posted by Stanley Muller on Nov 12th, 2026

Coya Therapeutics (NASDAQ:COYA – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright‘s price objective would indicate a potential upside of 460.75% from the stock’s current price.

Several other equities research analysts have also recently weighed in on COYA. Roth Capital restated a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 price target on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Thursday, October 15th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

View Our Latest Research Report on Coya Therapeutics

Coya Therapeutics Stock Up 1.6%

Shares of NASDAQ COYA opened at $3.21 on Thursday. The stock’s 50-day simple moving average is $4.34 and its two-hundred day simple moving average is $4.59. Coya Therapeutics has a twelve month low of $2.72 and a twelve month high of $6.62. The firm has a market capitalization of $75.31 million, a P/E ratio of -2.31 and a beta of 0.70.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.11). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative net margin of 643.44% and a negative return on equity of 66.91%. As a group, research analysts anticipate that Coya Therapeutics will post -1.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP grew its position in Coya Therapeutics by 1,200.0% during the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after purchasing an additional 12,000 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Coya Therapeutics during the second quarter valued at approximately $116,000. Cetera Investment Advisers grew its holdings in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Coya Therapeutics during the first quarter valued at approximately $161,000. Finally, Long Corridor Asset Management Ltd bought a new position in Coya Therapeutics in the 2nd quarter valued at approximately $227,000. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.